Population pharmacokinetics of piperacillin at two dose levels: Influence of nonlinear pharmacokinetics on the pharmacodynamic profile

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5715-5723

  Landersdorfer, Cornelia B ^a,b,c   Bulitta, Jurgen B ^a,b,c   Kirkpatrick, Carl M J ^b   Kinzig, Martina ^a   Holzgrabe, Ulrike ^d   Drusano, George L ^e   Stephan, Ulrich ^f   Sörgel, Fritz ^a,f  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Department of Neurological Surgery   (United States)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LOW DRUG DOSE; MALE; MICHAELIS CONSTANT; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PHARMACODYNAMICS; POPULATION RESEARCH; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MONTE CARLO METHOD; NONLINEAR DYNAMICS; PENICILLANIC ACID; PIPERACILLIN;

EID: 84868020712     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00937-12     Document Type: Article

References (41)

1. Ambrose PG, Bhavnani SM, Jones RN. 2003. Pharmacokineticspharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program. Antimicrob. Agents Chemother. 47:1643-1646.
2. Ambrose PG, et al. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79 - 86.
3. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int. J. Antimicrob. Agents 19:261-268.
4. Anonymous. 1999. Piperacillin sodium and tazobactam sodium (Zosyn) product information. Lederle Laboratories, Pearl River, NY.
5. Aronoff GR, Sloan RS, Brier ME, Luft FC. 1983. The effect of piperacillin dose on elimination kinetics in renal impairment. Eur. J. Clin. Pharmacol. 24:543-547.
6. Batra VK, Morrison JA, Lasseter KC, Joy VA. 1979. Piperacillin kinetics. Clin. Pharmacol. Ther. 26:41-53.
7. Bauer RJ. 2010. S-ADAPT/MCPEM user's guide (version 1.57). Software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
8. Beal SL, Sheiner LB, Boeckmann AJ. 2006. NONMEM user's guides (1989-2006). Icon Development Solutions, Ellicott City, MD.
9. Bergan T. 1981. Overview of acylureidopenicillin pharmacokinetics. Scand. J. Infect. Dis. Suppl. 29:33-48.
10. Bergan T, Williams JD. 1982. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 28:153-159.
11. Bulitta JB, Bingolbali A, Shin BS, Landersdorfer CB. 2011. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J. 13:201-211.
12. Bulitta JB, et al. 2010. Nonlinear pharmacokinetics of piperacillin in healthy volunteers: implications for optimal dosage regimens. Br. J. Clin. Pharmacol. 70:682-693.
13. Bulitta JB, et al. 2011. Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpiromein cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 55:2927-2936.
14. Bulitta JB, Landersdorfer CB. 2011. Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. AAPS J. 13:212-226.
15. Bulitta JB, et al. 2011. Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr. Pharm. Biotechnol. 12:2044-2061.
16. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
17. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
18. Drusano GL, Forrest A, Fiore D, Auger F, Caplan ES. 1984. Effect of saturable clearance during high-dose mezlocillin therapy. Antimicrob. Agents Chemother. 26:686-688.
19. European Committee on Antimicrobial Susceptibility Testing. 2012. EUCAST MIC distribution website. EUCAST, Voxjo, Sweden. http://www.eucast.org.
20. Evans MA, Wilson P, Leung T, Williams JD. 1978. Pharmacokinetics of piperacillin following intravenous administration. J. Antimicrob. Chemother. 4:255-261.
21. Flaherty JF, Barriere SL, Mordenti J, Gambertoglio JG. 1987. Effect of dose on pharmacokinetics and serum bactericidal activity of mezlocillin. Antimicrob. Agents Chemother. 31:895-898.
22. Kiffer CR, Mendes C, Kuti JL, Nicolau DP. 2004. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA program, South America 2002. Diagn. Microbiol. Infect. Dis. 49:109-116.
23. Kuti JL, Nightingale CH, Nicolau DP. 2004. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob. Agents Chemother. 48:2464-2470.
24. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. 2002. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn. Microbiol. Infect. Dis. 44:51-57.
25. Landersdorfer CB, et al. 2009. Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid. Antimicrob. Agents Chemother. 53:3902-3907.
26. Landersdorfer CB, et al. 2010. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br. J. Clin. Pharmacol. 69:167-178.
27. Lodise TP Jr, Lomaestro B, Rodvold KA, Danziger LH, Drusano GL. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactaminpatients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrob. Agents Chemother. 48:4718-4724.
28. Mangione A, Boudinot FD, Schultz RM, Jusko WJ. 1982. Dosedependent pharmacokinetics of mezlocillin in relation to renal impairment. Antimicrob. Agents Chemother. 21:428-435.
29. Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
30. Occhipinti DJ, et al. 1997. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens. Antimicrob. Agents Chemother. 41:2511-2517.
31. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J. 2010. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int. J. Antimicrob. Agents 35:156-163.
32. Schulin T. 2002. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J. Antimicrob. Chemother. 49:403-406.
33. Sorgel F, Kinzig M. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl A):39-60.
34. Sorgel F, Kinzig M. 1994. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med. 20(Suppl 3):S14-S20.
35. Spencker FB, Staber L, Lietz T, Schille R, Rodloff AC. 2003. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin. Microbiol. Infect. 9:370-379.
36. Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ, Verbist L. 1978. Piperacillin: human pharmacokinetics after intravenous and intramuscular administration. Antimicrob. Agents Chemother. 14:829-837.
37. Touw DJ. 1998. Clinical pharmacokinetics ofantimicrobial drugs incystic fibrosis. Pharm. World Sci. 20:149-160.
38. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. 2010. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet. 49:1-16.
39. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. 2002. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob. Agents Chemother. 46:2327-2332.
40. Vinks AA, Den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW. 2003. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusioninpatients with cystic fibrosis. Antimicrob. Agents Chemother. 47:541-547.
41. Welling PG, et al. 1983. Pharmacokinetics of piperacillin in subjects with various degrees of renal function. Antimicrob. Agents Chemother. 23: 881-887.